Plain-English translation of NCT06785116 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether a medication called dapagliflozin can help protect heart health in women after they've had high blood pressure during pregnancy. High blood pressure in pregnancy can increase a woman's risk of heart problems in the years after delivery. Researchers want to see if taking this medication for six months after delivery can reduce that risk.
Women who experience high blood pressure during pregnancy have a much higher chance of developing heart disease within the next few years. There are no proven treatments specifically designed to prevent these heart problems during the critical time right after delivery, so this study is exploring whether this medication might fill that gap.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly assigned to take either the study medication or a placebo (a pill with no active ingredient) once daily for six months after your baby is born. You'll have visits where your blood pressure and heart health will be monitored, and you'll complete questionnaires about your health. The study team will track how you're doing and watch for any side effects or changes in your cardiovascular health over those six months.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
United States